French pharma Servier completes two major deals totaling $5.15 billion to expand its oncology and rare disease portfolios.
Servier has finalized two significant acquisitions, totaling $5.15 billion, to bolster its presence in oncology and rare diseases. The company acquired Day One Biopharmaceuticals for $2.5 billion and Edgewise Therapeutics’ muscular dystrophy business for $2.65 billion in 2026.
These deals follow earlier AI-focused partnerships with InSilico Medicine and Iktos, reflecting Servier’s strategy to navigate evolving industry trends. The acquisitions aim to strengthen its pipeline amid shifting global pharmaceutical dynamics.
The moves underscore Servier’s aggressive M&A approach as it adapts to geopolitical and market challenges in the sector.